Tasrif Pharmaceutical

Tasrif Pharmaceutical is a private, preclinical oncology biotechnology company incorporated in New York in 2018. The company is focused on cancer immunotherapies targeting the poliovirus receptor, also known as CD155 or PVR, a tumor-associated antigen and component of the PVR-TIGIT immune checkpoint axis. Its lead disclosed program is TSRF 786C, a fully humanized IgG4 monoclonal antibody being developed for brain and systemic cancers expressing PVR. Tasrif has also described discovery-stage follow-on immunotherapeutic approaches derived from the same biology, including bispecific antibodies, antibody-drug conjugates, T-cell engagers, and anti-PVR CAR-T cells. The company appears to remain private and early stage, with no FDA-approved products and limited publicly disclosed financing or partnering activity.